CD38 is a protein that is found in high amounts on
cancer cells in
multiple myeloma (MM), making it a good target for new treatments. There are a few anti-CD38 antibodies being tested, like
daratumumab, but they have a limitation because they don't help immune cells called T cells kill the cancer cells very well. To get around this, scientists have made special antibodies that are two-in-one, they can bring T cells to the cancer cells and help them kill them. These special antibodies work even if the T cells don't normally recognize the cancer cells.
The researchers made a bunch of these two-in-one antibodies and tested how well they worked in a lab. They picked the best ones, called XmAb13243 and XmAb13551, which are really good at sticking to CD38 and
CD3, which are important for T cells. These antibodies worked very well in tests where they helped T cells kill cancer cells.
Unlike other two-in-one antibodies, these ones last a long time in animals and are easy to make. They also don't stick to other parts of the immune system that they shouldn't, which is good because it stops them from causing problems where they aren't needed.
The researchers tested these antibodies in mice and monkeys and found that they worked really well. They helped T cells kill the cancer cells and stopped the cancer from growing. The antibodies were much better than other treatments that are being tested.
The scientists think that these two-in-one antibodies could be a good way to treat multiple myeloma and other cancers that have a lot of CD38. They are planning to test them in people soon.
The people who worked on this study all work for a company called
Xencor, and they own shares in the company.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
